Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 Sep 3;74(9):1167-1176.
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial showed that MACEs were ...
Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint was the composite of coronary heart disease death, ...
In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and death.
Vascular reactivity to mental stress is associated with poor cardiovascular disease outcomes in females following acute coronary syndrome. · Risk Factors for ...
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial. / Jukema, J.W.; Szarek, M.; Zijlstra, L.E. et al.
All Episodes · Alirocumab in Patients with Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial ...
Acute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular disease ... Alirocumab and Polyvascular Disease in ODYSSEY OUTCOMES.
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial Article. Industry Collaboration International ...
People also ask
What are the new antithrombotic drugs in acute coronary syndrome?
What are the benefits of alirocumab?
What is the effect of low-density lipoprotein cholesterol lowering with alirocumab on stroke in Odyssey outcomes?
Methods: Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint was the composite of coronary heart disease ...